Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
Needham downgrades Biogen on slow growth of Alzheimer's drug
Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.
Needham downgrades Biogen to Hold on lack of share catalysts
Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...
Worldcrunch on MSN8h
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?
That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...
Biogen downgraded to Hold from Buy at Needham
Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...
Finanznachrichten12h
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ
OPUVIZ is one of the first wave aflibercept biosimilars in Europe OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's partnership EC ...
Global News16h
Global National homepage
The Conservative leader said he will work to bring foreign investment and industry back to Canada with policies similar to Trump's vows to slash taxes and regulations.
Australian Broadcasting Corporation17h
New South Wales
Veteran broadcaster Alan Jones has been charged with historical indecent assault and sexual touching offences spanning two decades.